Benjamin Filtjens, Vida Adeli, Soroush Mehraban, Andrea Sabo, Babak Taati, Andrea Iaboni
{"title":"Assessment of change in drug-induced parkinsonism in daily-life gait using vision-based machine learning.","authors":"Benjamin Filtjens, Vida Adeli, Soroush Mehraban, Andrea Sabo, Babak Taati, Andrea Iaboni","doi":"10.1371/journal.pdig.0001780","DOIUrl":null,"url":null,"abstract":"<p><p>Drug-induced parkinsonism is a potentially reversible movement disorder that may be subtle and difficult to monitor in residential dementia care. Vision-based machine learning analysis of gait may provide unobtrusive longitudinal monitoring around medication changes. We conducted a two-center cohort study of 61 residents with dementia receiving psychotropic medication. Hallway gait sequences were recorded using ceiling-mounted cameras and converted to three-dimensional body pose. A TabPFN classifier estimated UPDRS-III item 29 gait severity for each walk. We evaluated associations between acute antipsychotic (AP) and antidepressant (AD) dose reduction/cessation (≥50% dose reduction or cessation, 0-21 days after change) and daily mean predicted gait severity using linear mixed-effects models in ever-exposed participants, with complementary equal-weight paired analyses among participants observed in both medication states. In mixed-effects models, acute AP dose reduction/cessation was associated with lower predicted gait severity (β=-0.127, p = 0.022), whereas AD dose reduction/cessation was not (β=-0.060, p = 0.210). Equal-weight paired analyses found no statistically significant participant-average within-person change among paired participants (AP mean change = 0.031, 95% CI [-0.114, 0.176], p = 0.653; AD mean change =-0.021, 95% CI [-0.098, 0.056], p = 0.575), consistent with heterogeneous individual responses. Vision-based monitoring captured within-participant gait variation around psychotropic dose-reduction periods, but findings are associative. Larger prospective studies with documented reasons for medication changes are needed before using such monitoring to guide medication decisions.</p>","PeriodicalId":74465,"journal":{"name":"PLOS digital health","volume":"5 10","pages":"e0001780"},"PeriodicalIF":7.7000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671658/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLOS digital health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1371/journal.pdig.0001780","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Drug-induced parkinsonism is a potentially reversible movement disorder that may be subtle and difficult to monitor in residential dementia care. Vision-based machine learning analysis of gait may provide unobtrusive longitudinal monitoring around medication changes. We conducted a two-center cohort study of 61 residents with dementia receiving psychotropic medication. Hallway gait sequences were recorded using ceiling-mounted cameras and converted to three-dimensional body pose. A TabPFN classifier estimated UPDRS-III item 29 gait severity for each walk. We evaluated associations between acute antipsychotic (AP) and antidepressant (AD) dose reduction/cessation (≥50% dose reduction or cessation, 0-21 days after change) and daily mean predicted gait severity using linear mixed-effects models in ever-exposed participants, with complementary equal-weight paired analyses among participants observed in both medication states. In mixed-effects models, acute AP dose reduction/cessation was associated with lower predicted gait severity (β=-0.127, p = 0.022), whereas AD dose reduction/cessation was not (β=-0.060, p = 0.210). Equal-weight paired analyses found no statistically significant participant-average within-person change among paired participants (AP mean change = 0.031, 95% CI [-0.114, 0.176], p = 0.653; AD mean change =-0.021, 95% CI [-0.098, 0.056], p = 0.575), consistent with heterogeneous individual responses. Vision-based monitoring captured within-participant gait variation around psychotropic dose-reduction periods, but findings are associative. Larger prospective studies with documented reasons for medication changes are needed before using such monitoring to guide medication decisions.